ATE243045T1 - Behandlung von krebs durch verwendung von zytokin-exprimierender polynukleotiden und zusammensetzungen dafür - Google Patents
Behandlung von krebs durch verwendung von zytokin-exprimierender polynukleotiden und zusammensetzungen dafürInfo
- Publication number
- ATE243045T1 ATE243045T1 AT98960333T AT98960333T ATE243045T1 AT E243045 T1 ATE243045 T1 AT E243045T1 AT 98960333 T AT98960333 T AT 98960333T AT 98960333 T AT98960333 T AT 98960333T AT E243045 T1 ATE243045 T1 AT E243045T1
- Authority
- AT
- Austria
- Prior art keywords
- present
- cytokine
- provides
- cancer
- infectious
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Manufacturing & Machinery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6708797P | 1997-11-20 | 1997-11-20 | |
US7991498P | 1998-03-30 | 1998-03-30 | |
US10082098P | 1998-09-15 | 1998-09-15 | |
PCT/US1998/024830 WO1999026663A2 (en) | 1997-11-20 | 1998-11-20 | Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE243045T1 true ATE243045T1 (de) | 2003-07-15 |
Family
ID=27371088
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT08005898T ATE550042T1 (de) | 1997-11-20 | 1998-11-20 | Behandlung von krebs mithilfe cytokin- exprimierender polynukleotide und zusammensetzungen dafür |
AT98960333T ATE243045T1 (de) | 1997-11-20 | 1998-11-20 | Behandlung von krebs durch verwendung von zytokin-exprimierender polynukleotiden und zusammensetzungen dafür |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT08005898T ATE550042T1 (de) | 1997-11-20 | 1998-11-20 | Behandlung von krebs mithilfe cytokin- exprimierender polynukleotide und zusammensetzungen dafür |
Country Status (7)
Country | Link |
---|---|
US (2) | US7268120B1 (de) |
EP (2) | EP1987845B1 (de) |
JP (1) | JP2001523480A (de) |
AT (2) | ATE550042T1 (de) |
CA (2) | CA2641217A1 (de) |
DE (1) | DE69815707T2 (de) |
WO (1) | WO1999026663A2 (de) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6537776B1 (en) | 1999-06-14 | 2003-03-25 | Diversa Corporation | Synthetic ligation reassembly in directed evolution |
ATE550042T1 (de) | 1997-11-20 | 2012-04-15 | Vical Inc | Behandlung von krebs mithilfe cytokin- exprimierender polynukleotide und zusammensetzungen dafür |
ES2308069T3 (es) * | 1999-03-26 | 2008-12-01 | Vical Incorporated | Composiciones adyuvantes para realzar inmunorespuestas a las vacunas polinucleotido-basadas. |
WO2001009303A2 (en) * | 1999-07-30 | 2001-02-08 | Vical Inc. | Flt-3 LIGAND-ENCODING POLYNUCLEOTIDE AS A POLYNUCLEOTIDE-BASED VACCINE ENHANCER |
JP2004511425A (ja) * | 2000-02-08 | 2004-04-15 | ザ ペン ステート リサーチ ファウンデーション | 免疫療法に使用されるインターロイキン13受容体サブユニットアルファー2 |
EP1278551A2 (de) | 2000-04-21 | 2003-01-29 | Vical Incorporated | Zusammensetzungen und verfahren zur (in vivo) verabreichung der auf polynukleotiden-basierenden therapeutika |
WO2002074981A2 (en) | 2001-03-21 | 2002-09-26 | Isis Innovation Ltd. | Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase |
EP1832603B1 (de) | 2001-06-05 | 2010-02-03 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt, enkodierend für ein bakterielles Antigen sowie deren Verwendung |
DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
WO2005017130A2 (en) * | 2003-08-18 | 2005-02-24 | Glycotope Gmbh | Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses thereof |
DE102004042546A1 (de) * | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
CA2662226C (en) * | 2006-09-10 | 2020-08-04 | Glycotope Gmbh | Fully human high yield production system for improved antibodies and proteins |
EP1920781B1 (de) * | 2006-11-10 | 2015-03-04 | Glycotope GmbH | Zusammensetzungen die ein Core-1 positives Mikroorganismus enthalten und deren Verwendung zur Behandlung von Tumoren |
US20100330062A1 (en) | 2007-05-08 | 2010-12-30 | Koeffler H Phillip | Klotho protein and related compounds for the treatment and diagnosis of cancer |
US10555963B2 (en) | 2007-05-08 | 2020-02-11 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Klotho protein and related compounds for the treatment and diagnosis of cancer |
US9801818B2 (en) | 2007-12-31 | 2017-10-31 | Samyang Biopharmaceuticals Corporation | Method for stabilizing amphiphilic block copolymer micelle composition containing poorly water-soluble drug |
KR101024742B1 (ko) * | 2007-12-31 | 2011-03-24 | 주식회사 삼양사 | 탁산 함유 양친성 블록 공중합체 미셀 조성물 및 그 제조방법 |
KR101629071B1 (ko) | 2008-10-08 | 2016-06-09 | 인트렉손 코포레이션 | 다수의 면역조절자를 발현하는 조작된 세포 및 그 용도 |
US20110305769A1 (en) * | 2008-11-17 | 2011-12-15 | Enzon Pharmaceuticals, Inc. | Branched cationic lipids for nucleic acids delivery system |
DE102008060412B4 (de) | 2008-11-28 | 2023-03-30 | Dr. Ing. H.C. F. Porsche Aktiengesellschaft | Verbrennungsmotor |
US8492133B2 (en) | 2009-01-20 | 2013-07-23 | Ramot At Tel Aviv University, Ltd. | MIR-21 promoter driven targeted cancer therapy |
CN201397956Y (zh) * | 2009-03-23 | 2010-02-03 | 富士康(昆山)电脑接插件有限公司 | 电连接器组件 |
KR101857825B1 (ko) | 2010-03-04 | 2018-05-14 | 피페넥스 인크. | 변성 없이 가용성 재조합 인터페론 단백질을 제조하는 방법 |
EP3578205A1 (de) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | Pharmazeutische zusammensetzungen enthaltenbearbeitete nukleinsäuren und ihre medizinische verwendung |
SG190679A1 (en) | 2010-10-01 | 2013-07-31 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
BR112014004065A2 (pt) | 2011-08-22 | 2017-03-14 | Glycotope Gmbh | micro-organismos carregando um antígeno de tumor |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
SG11201401196WA (en) | 2011-10-03 | 2014-05-29 | Moderna Therapeutics Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
AU2012352180A1 (en) | 2011-12-16 | 2014-07-31 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
US20130225498A1 (en) * | 2012-02-29 | 2013-08-29 | Kyungpook National University Industry-Academic Cooperation Foundation | Composition for preventing or treating neurodegenerative diseases containing ccl5 |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9192651B2 (en) | 2012-04-02 | 2015-11-24 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
EP2844273B1 (de) | 2012-04-16 | 2018-01-31 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Polypeptid der klotho-variante und verwendung davon bei der therapie |
US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
EP3052106A4 (de) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynukleotide zur codierung immunmodulierender polypeptide |
MX2016004249A (es) | 2013-10-03 | 2016-11-08 | Moderna Therapeutics Inc | Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad. |
WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
RS63030B1 (sr) | 2015-09-17 | 2022-04-29 | Modernatx Inc | Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava |
CA3007955A1 (en) | 2015-12-10 | 2017-06-15 | Modernatx, Inc. | Lipid nanoparticles for delivery of therapeutic agents |
US10799463B2 (en) | 2015-12-22 | 2020-10-13 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
HUE061077T2 (hu) | 2016-05-18 | 2023-05-28 | Modernatx Inc | Interleukin-12 (IL12) kódoló polinukleotidok és felhasználásuk |
WO2018089540A1 (en) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
CA3056133A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
CA3055653A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
ES2940259T3 (es) | 2017-03-15 | 2023-05-04 | Modernatx Inc | Compuesto y composiciones para la administración intracelular de agentes terapéuticos |
EP3596108A4 (de) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | Gezielte immuntoleranz |
JP7285220B2 (ja) | 2017-05-18 | 2023-06-01 | モデルナティエックス インコーポレイテッド | 連結したインターロイキン-12(il12)ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子 |
WO2018217989A1 (en) | 2017-05-24 | 2018-11-29 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
BR112019024556A2 (pt) | 2017-05-24 | 2020-06-23 | Novartis Ag | Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
RS65580B1 (sr) | 2018-05-18 | 2024-06-28 | Daiichi Sankyo Co Ltd | Anti-muc1-eksatekan antitelo-lek konjugat |
US11739146B2 (en) | 2019-05-20 | 2023-08-29 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
EP4031524A1 (de) | 2019-09-19 | 2022-07-27 | ModernaTX, Inc. | Lipidverbindungen mit verzweigtem ende und zusammensetzungen zur intrazellulären abgabe therapeutischer mittel |
US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
WO2024015586A1 (en) * | 2022-07-15 | 2024-01-18 | Whitehead Institute For Biomedical Research | Compositions and methods for treating cancer with interferon-omega and analogs thereof |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2942780A1 (de) | 1979-10-23 | 1981-05-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | Eukaryotische zellen, eukaryotische protoplasten und vielzellige eukaryotische lebende organismen mit einem gehalt an durch lipidvesikel eingebrachter dna, verfahren zu ihrer herstellung von gen-produkten, zur immunisierung und zur behebung genetisch bedingter defekte |
US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
US5098703A (en) | 1982-01-15 | 1992-03-24 | Cetus Corporation | Interferon-alpha 76 |
US4975276A (en) | 1982-01-15 | 1990-12-04 | Cetus Corporation | Interferon-alpha 54 |
US4973479A (en) | 1982-01-15 | 1990-11-27 | Cetus Corporation | Interferon-α61 |
US4695543A (en) | 1982-03-23 | 1987-09-22 | Bristol-Myers Company | Alpha Interferon GX-1 |
US4748233A (en) | 1982-03-23 | 1988-05-31 | Bristol-Myers Company | Alpha-interferon Gx-1 |
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US5229272A (en) | 1989-04-25 | 1993-07-20 | Igen, Inc. | Catalytic antibody components |
US4892743A (en) | 1983-12-21 | 1990-01-09 | Schering Corporation | Novel hybrid interferon species |
EP0170204B1 (de) | 1984-08-01 | 1991-09-25 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Neue genetische Sequenzen, die durch sie codierten Interferon-Peptide vom Typ I und diese sie produzierende Organismen |
US5120832A (en) | 1984-08-27 | 1992-06-09 | Genentech, Inc. | Distinct family of human leukocyte interferons |
US5231176A (en) | 1984-08-27 | 1993-07-27 | Genentech, Inc. | Distinct family DNA encoding of human leukocyte interferons |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
DE3607835A1 (de) | 1986-03-10 | 1987-09-24 | Boehringer Ingelheim Int | Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung |
FR2619719B1 (fr) | 1987-09-01 | 1991-05-10 | Sanofi Sa | Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices |
US5268169A (en) | 1989-02-02 | 1993-12-07 | Roussel Uclaf | Treatment method of ovarian cancer using interferon gamma |
US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
US6867195B1 (en) | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
ES2200016T3 (es) | 1989-03-21 | 2004-03-01 | Vical Incorporated | Expresion de secuencias polinucleotidicas exogenas en un vertebrado. |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
US6214804B1 (en) | 1989-03-21 | 2001-04-10 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
US5676954A (en) | 1989-11-03 | 1997-10-14 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
ATE158615T1 (de) | 1990-03-20 | 1997-10-15 | Univ Columbia | Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region |
US20030186913A1 (en) | 1990-03-21 | 2003-10-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
US6706694B1 (en) * | 1990-03-21 | 2004-03-16 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
US6228844B1 (en) * | 1991-11-12 | 2001-05-08 | Vical Incorporated | Stimulating vascular growth by administration of DNA sequences encoding VEGF |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
US5429127A (en) | 1991-09-12 | 1995-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Thin wall endotracheal tube |
WO1993024640A2 (en) | 1992-06-04 | 1993-12-09 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
US5910488A (en) | 1993-06-07 | 1999-06-08 | Vical Incorporated | Plasmids suitable for gene therapy |
US5578475A (en) | 1993-07-12 | 1996-11-26 | Life Technologies, Inc. | Composition and methods for transfecting eukaryotic cells |
WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
JPH09505593A (ja) | 1993-11-24 | 1997-06-03 | メガバイオス・コーポレイション | ピペラジンの両親媒性誘導体 |
JPH09505808A (ja) | 1993-11-24 | 1997-06-10 | メガバイオス・コーポレイション | グアニジンの両親媒性誘導体 |
US5674908A (en) | 1993-12-20 | 1997-10-07 | Life Technologies, Inc. | Highly packed polycationic ammonium, sulfonium and phosphonium lipids |
US5641665A (en) | 1994-11-28 | 1997-06-24 | Vical Incorporated | Plasmids suitable for IL-2 expression |
US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
US5830430A (en) | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
US5830878A (en) | 1995-06-07 | 1998-11-03 | Megabios Corporation | Cationic lipid: DNA complexes for gene targeting |
US5932241A (en) | 1995-06-07 | 1999-08-03 | Valentis, Incorporated | Cationic lipid DNA complexes for gene targeting |
US5811406A (en) | 1995-06-07 | 1998-09-22 | Regents Of The University Of California | Dry powder formulations of polynucleotide complexes |
DE19521412A1 (de) | 1995-06-14 | 1996-12-19 | Boehringer Mannheim Gmbh | Neue kationische und polykationische Amphiphile, diese enthaltende Reagenzien und deren Verwendung |
EP0835130A1 (de) * | 1995-06-19 | 1998-04-15 | University Of Medicine & Dentistry Of New Jersey | Gentherapie von soliden tumoren mit interferone allein oder mit anderen immunoeffektoren proteinen |
CA2237316C (en) | 1995-11-30 | 2012-06-26 | Vical Incorporated | Complex cationic lipids |
WO1998008947A1 (en) | 1995-12-19 | 1998-03-05 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Enhancement of dna immunization through the use of cytokines |
WO1997030089A1 (en) | 1996-02-13 | 1997-08-21 | Regents Of The University Of California | Novel antibody-cytokine fusion protein, and methods of making and using the same |
US5994317A (en) | 1996-04-09 | 1999-11-30 | Vical Incorporated | Quaternary cytofectins |
US5861397A (en) | 1996-10-03 | 1999-01-19 | Vical Incorporated | Piperazine based cytofectins |
ATE550042T1 (de) | 1997-11-20 | 2012-04-15 | Vical Inc | Behandlung von krebs mithilfe cytokin- exprimierender polynukleotide und zusammensetzungen dafür |
AU4219399A (en) | 1998-06-08 | 1999-12-30 | Valentis, Inc. | Formulations for electroporation |
ES2308069T3 (es) | 1999-03-26 | 2008-12-01 | Vical Incorporated | Composiciones adyuvantes para realzar inmunorespuestas a las vacunas polinucleotido-basadas. |
US6696424B1 (en) | 1999-05-28 | 2004-02-24 | Vical Incorporated | Cytofectin dimers and methods of use thereof |
EP1278551A2 (de) * | 2000-04-21 | 2003-01-29 | Vical Incorporated | Zusammensetzungen und verfahren zur (in vivo) verabreichung der auf polynukleotiden-basierenden therapeutika |
JP2005533727A (ja) | 2002-07-24 | 2005-11-10 | サン キュ パク | インスタント食品の調理状態及び完了表示装置 |
-
1998
- 1998-11-20 AT AT08005898T patent/ATE550042T1/de active
- 1998-11-20 WO PCT/US1998/024830 patent/WO1999026663A2/en active IP Right Grant
- 1998-11-20 CA CA002641217A patent/CA2641217A1/en not_active Abandoned
- 1998-11-20 EP EP08005898A patent/EP1987845B1/de not_active Expired - Lifetime
- 1998-11-20 CA CA002309766A patent/CA2309766C/en not_active Expired - Fee Related
- 1998-11-20 JP JP2000521864A patent/JP2001523480A/ja active Pending
- 1998-11-20 DE DE69815707T patent/DE69815707T2/de not_active Revoked
- 1998-11-20 EP EP98960333A patent/EP1032428B1/de not_active Revoked
- 1998-11-20 AT AT98960333T patent/ATE243045T1/de not_active IP Right Cessation
-
2000
- 2000-04-21 US US09/557,907 patent/US7268120B1/en not_active Expired - Fee Related
-
2007
- 2007-02-23 US US11/709,868 patent/US7470675B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1032428B1 (de) | 2003-06-18 |
US7268120B1 (en) | 2007-09-11 |
JP2001523480A (ja) | 2001-11-27 |
EP1032428A2 (de) | 2000-09-06 |
CA2309766A1 (en) | 1999-06-03 |
DE69815707T2 (de) | 2004-07-01 |
EP1987845B1 (de) | 2012-03-21 |
CA2309766C (en) | 2008-09-30 |
US20070225243A1 (en) | 2007-09-27 |
WO1999026663A3 (en) | 2000-01-06 |
WO1999026663A2 (en) | 1999-06-03 |
EP1987845A3 (de) | 2010-09-29 |
US7470675B2 (en) | 2008-12-30 |
DE69815707D1 (de) | 2003-07-24 |
CA2641217A1 (en) | 1999-06-03 |
EP1987845A2 (de) | 2008-11-05 |
ATE550042T1 (de) | 2012-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE243045T1 (de) | Behandlung von krebs durch verwendung von zytokin-exprimierender polynukleotiden und zusammensetzungen dafür | |
NO20004911D0 (no) | Antitumormiddel | |
DK1058562T3 (da) | Præparater og fremgangsmåder til behandling af tumorer | |
NO20071426L (no) | Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib | |
DE69830072D1 (de) | Radioaktive zusammensetzungen zur behandlung von prostatatumoren | |
DK0957903T3 (da) | Norbornen- og norbornandiolforbindelser til behandling af pigmenteringslidelser, neurodegenerative sygdomme eller proliferative hudlidelser | |
BG101284A (en) | Compounds and methods for cancer treatment | |
BR9808881A (pt) | Compostos para imunoterapia de câncer de próstata e métodos para seu uso | |
CY1109340T1 (el) | Μεθοδοι θεραπειας bcl-2 διαταραχης χρησιμοποιωντας bcl-2 αντιπληροφοριακα ολιγομερη | |
NO20071428L (no) | Kombinasjon inneholdende ZD6474 og Imatinib | |
ATE113295T1 (de) | Tumornekrosefaktor, verfahren zu seiner herstellung, denselben enthaltende zusammensetzungen, dafür kodierende dns und diese dns verwendendes testverfahren. | |
DE69534946D1 (de) | Verwendung von nackten Polynukleotiden zur Herstellung eines Medikaments für die Behandlung von Tumoren | |
DE69911210D1 (de) | Verwendung von piperin und derivate davon zur behandlung von hautpigmentierungstörungen und hautkrebs | |
DK471386A (da) | Farmaceutisk komposition til behandling af leukopeni | |
ATE530184T1 (de) | Piperazinon-verbindungen als tumor- und krebsbekämpfende wirkstoffe | |
DE69734574D1 (de) | Rekombinante adenovirenvektoren zur gentherapie der menschlichen krebse | |
ES2189165T3 (es) | Nuevos compuestos macrociclicos como inhibidores de metaloproteasa. | |
ES2071995T3 (es) | Composicion para la activacion de macrofagia. | |
AR019844A1 (es) | Polipeptidos composicion farmaceutica, procedimiento para preparar dicha composicion metodo para tratar y prevenir el cancer y metodo para inhibir elcrecimiento de celulas tumorales | |
ATE369147T1 (de) | Verwendung von stimulierten mononuklearen zellen des peripheren blutes zur behandlung von krebserkrankungen | |
DE69814691D1 (de) | Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten | |
DK1162985T3 (da) | Matrixproteinsammensætninger til induktion af apoptose | |
DE59101818D1 (de) | Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung. | |
ATE354373T1 (de) | Verabreichung von gammaglobulinen zur behandlung von lymphomen | |
EA200600987A1 (ru) | Применение сирамезина в лечении злокачественных опухолей |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |